For metastatic and advanced prostate cancer, androgen deprivation therapy (ADT) has been found to be mostly palliative with nearly all cases eventually progressing to castration-resistant prostate cancer (CRPC). CRPC is characterized as biochemical, clinical, or radiographic progression despite having castrate levels of serum testosterone. Once confirmation that serum testosterone is at castration levels, management of prostate cancer is based on a variety of factors.
How familiar are you with the management of CRPC? Test your knowledge with this quick quiz.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Evelyn S. Marienberg. Fast Five Quiz: Castration-Resistant Metastatic and Advanced Prostate Cancer Management - Medscape - Nov 08, 2022.